Astrana Health (AMEH) Stock Forecast, Price Target & Predictions
AMEH Stock Forecast
Astrana Health stock forecast is as follows: an average price target of $48.50 (represents a 22.26% upside from AMEH’s last price of $39.67) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AMEH Price Target
The average price target for Astrana Health (AMEH) is $48.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $40.00. This represents a potential 22.26% upside from AMEH's last price of $39.67.
AMEH Analyst Ratings
According to 3 Wall Street analysts, Astrana Health's rating consensus is 'Buy'. The analyst rating breakdown for AMEH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Astrana Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 19, 2022 | - | Lake Street | $40.00 | $29.45 | 35.82% | 0.83% |
| Aug 08, 2022 | - | Barclays | $57.00 | $54.21 | 5.15% | 43.69% |
The latest Astrana Health stock forecast, released on Dec 19, 2022 by Lake Street company, set a price target of $40.00, which represents a 35.82% increase from the stock price at the time of the forecast ($29.45), and a 0.83% increase from AMEH last price ($39.67).
Astrana Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $39.67 | $39.67 | $39.67 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Astrana Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Astrana Health's last price of $39.67. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 19, 2022 | Lake Street | - | Buy | Initialise |
| Sep 21, 2022 | William Blair | - | Outperform | Initialise |
| Aug 08, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
Astrana Health's last stock rating was published by Lake Street on Dec 19, 2022. The company Initialise its AMEH rating from "null" to "Buy".
Astrana Health Financial Forecast
Astrana Health Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $348.21M | $335.62M | $292.85M | $315.31M | $268.14M | $261.70M | $193.56M | $173.53M | $174.39M | $178.39M | $163.91M | $163.90M | $154.78M | $128.65M | $94.69M | $166.92M | $122.23M |
| Avg Forecast | $454.12M | $424.94M | $429.00M | $346.37M | $350.10M | $212.52M | $201.42M | $189.49M | $167.64M | $193.20M | $183.11M | $172.26M | $175.64M | $166.46M | $152.40M | $60.85M | $60.04M | $218.48M | $95.52M | $166.13M | $62.73M | $175.29M |
| High Forecast | $454.12M | $424.94M | $466.10M | $352.30M | $350.10M | $255.03M | $241.70M | $227.38M | $201.17M | $231.84M | $219.73M | $206.71M | $210.77M | $199.75M | $182.88M | $73.02M | $72.05M | $262.18M | $114.62M | $199.35M | $75.28M | $210.34M |
| Low Forecast | $454.12M | $424.94M | $391.90M | $335.00M | $350.10M | $170.02M | $161.13M | $151.59M | $134.11M | $154.56M | $146.48M | $137.81M | $140.51M | $133.17M | $121.92M | $48.68M | $48.03M | $174.79M | $76.42M | $132.90M | $50.18M | $140.23M |
| # Analysts | 1 | 1 | 3 | 4 | 2 | 17 | 15 | 14 | 19 | 16 | 19 | 11 | 13 | 8 | 9 | 9 | 12 | 8 | 17 | 10 | 18 | 10 |
| Surprise % | - | - | - | - | - | 1.64% | 1.67% | 1.55% | 1.88% | 1.39% | 1.43% | 1.12% | 0.99% | 1.05% | 1.17% | 2.69% | 2.73% | 0.71% | 1.35% | 0.57% | 2.66% | 0.70% |
Astrana Health's average Quarter revenue forecast for Sep 23 based on 2 analysts is $350.10M, with a low forecast of $350.10M, and a high forecast of $350.10M. AMEH's average Quarter revenue forecast represents a 0.54% increase compared to the company's last Quarter revenue of $348.21M (Jun 23).
Astrana Health EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 4 | 2 | 17 | 15 | 14 | 19 | 16 | 19 | 11 | 13 | 8 | 9 | 9 | 12 | 8 | 17 | 10 | 18 | 10 |
| EBITDA | - | - | - | - | - | $38.51M | $33.36M | $20.77M | $55.20M | $24.70M | $32.68M | $16.60M | $90.54M | $26.95M | $43.31M | $20.51M | $12.46M | $22.16M | $19.64M | $770.19K | $58.23M | $14.42M |
| Avg Forecast | $60.34M | $56.47M | $21.72M | $46.03M | $46.52M | $35.23M | $19.75M | $15.75M | $31.57M | $32.02M | $17.95M | $14.32M | $29.11M | $16.32M | $28.70M | $32.78M | $10.14M | $16.89M | $8.18M | $5.89M | $19.14M | $11.98M |
| High Forecast | $60.34M | $56.47M | $26.07M | $46.81M | $46.52M | $42.27M | $23.70M | $18.90M | $37.89M | $38.43M | $21.54M | $17.19M | $34.93M | $19.58M | $34.44M | $39.34M | $12.17M | $20.27M | $9.81M | $7.07M | $22.97M | $14.38M |
| Low Forecast | $60.34M | $56.47M | $17.38M | $44.51M | $46.52M | $28.18M | $15.80M | $12.60M | $25.26M | $25.62M | $14.36M | $11.46M | $23.29M | $13.06M | $22.96M | $26.23M | $8.12M | $13.51M | $6.54M | $4.72M | $15.31M | $9.59M |
| Surprise % | - | - | - | - | - | 1.09% | 1.69% | 1.32% | 1.75% | 0.77% | 1.82% | 1.16% | 3.11% | 1.65% | 1.51% | 0.63% | 1.23% | 1.31% | 2.40% | 0.13% | 3.04% | 1.20% |
2 analysts predict AMEH's average Quarter EBITDA for Sep 23 to be $46.52M, with a high of $46.52M and a low of $46.52M. This is 20.80% upper than Astrana Health's previous annual EBITDA (Jun 23) of $38.51M.
Astrana Health Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 4 | 2 | 17 | 15 | 14 | 19 | 16 | 19 | 11 | 13 | 8 | 9 | 9 | 12 | 8 | 17 | 10 | 18 | 10 |
| Net Income | - | - | - | - | - | $13.17M | $14.62M | $471.00K | $25.99M | $11.40M | $14.26M | $-19.31M | $59.53M | $13.15M | $16.71M | $81.00M | $4.05M | $10.74M | $10.66M | $-2.45M | $38.63M | $7.87M |
| Avg Forecast | $72.32M | $63.00M | $11.14M | $7.98M | $15.48M | $10.21M | $10.13M | $13.46M | $15.25M | $9.28M | $9.21M | $12.24M | $8.44M | $8.37M | $13.86M | $5.03M | $3.04M | $4.76M | $2.32M | $245.03K | $6.07M | $3.46M |
| High Forecast | $72.32M | $63.00M | $13.37M | $9.38M | $15.48M | $12.25M | $12.15M | $16.16M | $18.30M | $11.14M | $11.05M | $14.69M | $10.13M | $10.04M | $16.64M | $6.04M | $3.65M | $5.72M | $2.78M | $294.04K | $7.29M | $4.16M |
| Low Forecast | $72.32M | $63.00M | $8.91M | $7.04M | $15.48M | $8.17M | $8.10M | $10.77M | $12.20M | $7.43M | $7.36M | $9.79M | $6.75M | $6.70M | $11.09M | $4.03M | $2.43M | $3.81M | $1.85M | $196.03K | $4.86M | $2.77M |
| Surprise % | - | - | - | - | - | 1.29% | 1.44% | 0.03% | 1.70% | 1.23% | 1.55% | -1.58% | 7.05% | 1.57% | 1.21% | 16.10% | 1.33% | 2.25% | 4.60% | -10.00% | 6.36% | 2.27% |
Astrana Health's average Quarter net income forecast for Sep 23 is $15.48M, with a range of $15.48M to $15.48M. AMEH's average Quarter net income forecast represents a 17.57% increase compared to the company's last Quarter net income of $13.17M (Jun 23).
Astrana Health SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 4 | 2 | 17 | 15 | 14 | 19 | 16 | 19 | 11 | 13 | 8 | 9 | 9 | 12 | 8 | 17 | 10 | 18 | 10 |
| SG&A | - | - | - | - | - | $24.06M | $21.18M | $24.45M | $21.39M | $19.89M | $11.94M | $16.60M | $14.20M | $9.46M | $16.27M | $11.56M | $11.83M | $7.95M | $11.82M | $10.26M | $9.03M | $11.47M |
| Avg Forecast | $31.57M | $29.54M | $8.02M | $24.08M | $24.34M | $11.45M | $7.29M | $16.23M | $14.84M | $10.41M | $6.62M | $14.76M | $9.47M | $6.02M | $13.50M | $8.25M | $8.88M | $10.22M | $7.72M | $18.01M | $6.02M | $14.91M |
| High Forecast | $31.57M | $29.54M | $9.62M | $24.49M | $24.34M | $13.74M | $8.74M | $19.48M | $17.81M | $12.50M | $7.95M | $17.71M | $11.36M | $7.23M | $16.19M | $9.91M | $10.65M | $12.27M | $9.26M | $21.61M | $7.23M | $17.90M |
| Low Forecast | $31.57M | $29.54M | $6.41M | $23.29M | $24.34M | $9.16M | $5.83M | $12.99M | $11.88M | $8.33M | $5.30M | $11.81M | $7.57M | $4.82M | $10.80M | $6.60M | $7.10M | $8.18M | $6.18M | $14.41M | $4.82M | $11.93M |
| Surprise % | - | - | - | - | - | 2.10% | 2.91% | 1.51% | 1.44% | 1.91% | 1.80% | 1.13% | 1.50% | 1.57% | 1.21% | 1.40% | 1.33% | 0.78% | 1.53% | 0.57% | 1.50% | 0.77% |
Astrana Health's average Quarter SG&A projection for Sep 23 is $24.34M, based on 2 Wall Street analysts, with a range of $24.34M to $24.34M. The forecast indicates a 1.17% rise compared to AMEH last annual SG&A of $24.06M (Jun 23).
Astrana Health EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 3 | 4 | 2 | 17 | 15 | 14 | 19 | 16 | 19 | 11 | 13 | 8 | 9 | 9 | 12 | 8 | 17 | 10 | 18 | 10 |
| EPS | - | - | - | - | - | $0.28 | $0.31 | $0.01 | $0.58 | $0.25 | $0.32 | $-0.43 | $1.36 | $0.31 | $0.70 | $2.30 | $0.08 | $0.31 | $0.31 | $-0.07 | $1.17 | $0.24 |
| Avg Forecast | $1.54 | $1.34 | $0.35 | $0.17 | $0.33 | $1.19 | $1.43 | $1.95 | $1.27 | $1.15 | $1.43 | $1.89 | $1.01 | $0.14 | $0.18 | $0.05 | $0.03 | $0.18 | $0.03 | $0.14 | $0.06 | $0.13 |
| High Forecast | $1.54 | $1.34 | $0.37 | $0.20 | $0.33 | $1.19 | $1.43 | $1.95 | $1.27 | $1.15 | $1.63 | $2.15 | $1.15 | $0.17 | $0.22 | $0.06 | $0.04 | $0.22 | $0.04 | $0.17 | $0.07 | $0.16 |
| Low Forecast | $1.54 | $1.34 | $0.32 | $0.15 | $0.33 | $1.19 | $1.43 | $1.95 | $1.27 | $1.15 | $1.29 | $1.70 | $0.91 | $0.11 | $0.15 | $0.04 | $0.02 | $0.14 | $0.03 | $0.11 | $0.05 | $0.10 |
| Surprise % | - | - | - | - | - | 0.23% | 0.22% | 0.01% | 0.46% | 0.22% | 0.22% | -0.23% | 1.34% | 2.21% | 3.89% | 46.00% | 2.76% | 1.72% | 10.33% | -0.51% | 19.50% | 1.85% |
According to 2 Wall Street analysts, Astrana Health's projected average Quarter EPS for Sep 23 is $0.33, with a low estimate of $0.33 and a high estimate of $0.33. This represents a 17.86% increase compared to AMEH previous annual EPS of $0.28 (Jun 23).
Astrana Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCSG | Healthcare Services Group | $11.66 | $17.33 | 48.63% | Hold |
| SGRY | Surgery Partners | $32.16 | $47.50 | 47.70% | Buy |
| AMED | Amedisys | $97.15 | $143.38 | 47.59% | Hold |
| EHAB | Enhabit | $8.16 | $10.25 | 25.61% | Hold |
| OPCH | Option Care Health | $31.11 | $38.00 | 22.15% | Buy |
| AMEH | Astrana Health | $40.82 | $48.50 | 18.81% | Buy |
| INNV | InnovAge | $5.99 | $6.80 | 13.52% | Hold |
| SEM | Select Medical | $35.30 | $40.00 | 13.31% | Buy |
| ACHC | Acadia Healthcare Company | $77.94 | $84.89 | 8.92% | Buy |
| EHC | Encompass Health | $92.45 | $93.17 | 0.78% | Buy |
| ADUS | Addus HomeCare | $132.52 | $123.00 | -7.18% | Buy |
| UHS | Universal Health Services | $234.69 | $208.47 | -11.17% | Hold |
| PNTG | Pennant Group | $34.99 | $30.67 | -12.35% | Buy |
| ENSG | Ensign Group | $151.00 | $124.40 | -17.62% | Buy |
AMEH Forecast FAQ
Is Astrana Health a good buy?
Yes, according to 3 Wall Street analysts, Astrana Health (AMEH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of AMEH's total ratings.
What is AMEH's price target?
Astrana Health (AMEH) average price target is $48.5 with a range of $40 to $57, implying a 22.26% from its last price of $39.67. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Astrana Health stock go up soon?
According to Wall Street analysts' prediction for AMEH stock, the company can go up by 22.26% (from the last price of $39.67 to the average price target of $48.5), up by 43.69% based on the highest stock price target, and up by 0.83% based on the lowest stock price target.
Can Astrana Health stock reach $60?
AMEH's average twelve months analyst stock price target of $48.5 does not support the claim that Astrana Health can reach $60 in the near future.
What are Astrana Health's analysts' financial forecasts?
AMEH's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $1.11B (high $1.2B, low $1.02B), average EBITDA is $147.52M (high $159.3M, low $135.02M), average net income is $43.8M (high $49.27M, low $38.79M), average SG&A $67.16M (high $71.32M, low $62.62M), and average EPS is $3.12 (high $3.15, low $3.1).
Did the AMEH's actual financial results beat the analysts' financial forecasts?
Based on Astrana Health's last annual report (Dec 2022), the company's revenue was $1.14B, beating the average analysts forecast of $733.43M by 55.16%. Apple's EBITDA was $133.35M, beating the average prediction of $97.3M by 37.05%. The company's net income was $49.05M, beating the average estimation of $47.2M by 3.92%. Apple's SG&A was $77.67M, beating the average forecast of $48.11M by 61.43%. Lastly, the company's EPS was $1.09, missing the average prediction of $5.81 by -81.24%. In terms of the last quarterly report (Jun 2023), Astrana Health's revenue was $348.21M, beating the average analysts' forecast of $212.52M by 63.85%. The company's EBITDA was $38.51M, beating the average prediction of $35.23M by 9.33%. Astrana Health's net income was $13.17M, beating the average estimation of $10.21M by 28.98%. The company's SG&A was $24.06M, beating the average forecast of $11.45M by 110.03%. Lastly, the company's EPS was $0.28, missing the average prediction of $1.19 by -76.52%